Arazasetron besylate
SENS-401-202
Phase 2 small_molecule active
Quick answer
Arazasetron besylate for Cisplatine induced hearing loss is a Phase 2 program (small_molecule) at Orion with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Orion
- Indication
- Cisplatine induced hearing loss
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active